Please enable Javascript
mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
Evaluating MDT Without ADT in Patients With Solitary Oligorecurrent Prostate Cancer
David Ambinder, MD
mHSPC
|
February 23, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Read More
Assessing Utilization Patterns of mHSPC Treatment in a Community Oncology Practice Setting
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Read More
Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment Settings
Tanya Dorff, MD
mHSPC
|
February 13, 2023
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
View More
The Future of Personalized Care in Oligometastatic Prostate Cancer
Matthew Deek, MD
mHSPC
|
January 31, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
View More
High-Risk Mutations in Oligometastatic Prostate Cancer Patients
Matthew Deek, MD
mHSPC
|
January 31, 2023
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
View More
PSMA Imaging in Oligometastatic Prostate Cancer
Matthew Deek, MD
Next-Generation Imaging
|
January 31, 2023
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
View More
MDT in omCSPC in the ORIOLE and STOMP Trials
Matthew Deek, MD
mHSPC
|
January 31, 2023
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
View More
Safety and Efficacy of PSMA-RLT in Early-Stage and Hormone-Sensitive Prostate Cancer
Emily Menendez
RLT-PSMA
|
January 12, 2023
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Read More
Circulating Tumor Cells May Predict Docetaxel Response in CRPC and mHSPC
Emily Menendez
mCRPC
|
January 4, 2023
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
Read More
Serum Testosterone-Measuring Assay Predicts Response to Castration in mHSPC
Zachary Bessette
mHSPC
|
December 7, 2022
High testosterone levels measured by a liquid chromatography-tandem mass spectrometry assay may predict castration response.
Read More
Daniel George on the Future of mHSPC Treatment
The Uromigos
Uromigos Live and Unplugged
|
November 4, 2022
Daniel George, MD, Duke University School of Medicine, gives us insight on what to expect from the future of mHSPC treatment.
View More
Neeraj Agarwal on the Future of mHSPC Treatment
The Uromigos
Uromigos Live and Unplugged
|
November 4, 2022
Neeraj Agarwal, MD, Professor of Medicine, gives his outlook on the future of cancer care and treatment for mHSPC in 2027.
View More
Michael Morris on the Future of mHSPC Treatment
The Uromigos
Uromigos Live and Unplugged
|
November 4, 2022
Michael Morris, MD, of Memorial Sloan Kettering Cancer Center gives his predictions for the future of mHSPC treatment.
View More
Overall Survival Results of STAMPEDE Protocol Phase 3 Trials
Akhil Abraham Saji, MD
Journal
|
October 24, 2022
Abiraterone acetate + prednisolone is compared to enzalutamide + AAP for mHSPC cancer starting androgen-deprivation therapy.
Read More
Zoledronic Acid Benefited Those With Bone Mets Regardless of HSPC/CRPC Status
Leah Lawrence
Prostate Cancer
|
October 18, 2022
Zoledronic acid did not improve survival outcomes in patients outside of metastatic castration-resistant disease.
Read More
Abiraterone Acetate, Prednisolone, and Enzalutamide With ADT in mHSPC
Patrick Daly
ESMO 2022
|
September 12, 2022
Late-breaking data from 2 randomized phase 3 trials that followed STAMPEDE protocol were presented at the ESMO Congress 2022.
Read More
FDA Approves Darolutamide, Docetaxel Combination for Metastatic Hormone-Sensitive Prostate Cancer
Cecilia Brown
mHSPC
|
August 9, 2022
The FDA has approved the use of darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer.
Read More
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study
GU Oncology Now Editors
mHSPC
|
June 3, 2022
...
Read More
DNA Damage Repair Gene Germline Profiling for Metastatic Prostate Cancer Patients
GU Oncology Now Editors
mCRPC
|
June 2, 2022
Researchers evaluate the frequency of germline DDRg mutations in metastatic prostate cancer patients of different ancestries.
Read More
The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context
GU Oncology Now Editors
mHSPC
|
May 27, 2022
...
Read More
Load More
Advertisement
Advertisement
Advertisement